Heron Therapeutics (HRTX) Inventory (2016 - 2026)

Heron Therapeutics (HRTX) has reported Inventory for 11 consecutive years, with $90.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory rose 24.15% year-over-year to $90.6 million; the trailing twelve-month figure through Jun 2026 stood at $90.6 million (up 24.15% YoY), and the FY2025 full-year result was $92.7 million, up 74.47% from the prior year.
• Inventory fell to $90.6 million in Q2 2026 per HRTX's latest filing, from $92.5 million in the prior quarter.
• Across five years, Inventory topped out at $92.7 million in Q4 2025 and bottomed at $42.0 million in Q3 2023.
• Historically, Inventory has averaged $59.2 million across 5 years, with a median of $53.9 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Inventory slipped 27.23% in 2023, then jumped 74.47% in 2025.
• Over 5 years, Inventory stood at $54.6 million in 2022, then declined by 22.84% to $42.1 million in 2023, then advanced by 26.24% to $53.2 million in 2024, then jumped by 74.47% to $92.7 million in 2025, then fell by 2.33% to $90.6 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $90.6 million, $92.5 million, and $92.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.